Kuehn Law is investigating Corcept Therapeutics for allegedly failing to disclose FDA concerns about the clinical development of relacorilant, a drug candidate for Cushing’s syndrome. The lawsuit claims the company misled investors by promoting expected FDA approval while hiding risks of rejection. Shareholders who bought Corcept stock before October 31, 2024, are encouraged to contact the law firm to protect their rights. This case highlights the importance of transparency in drug approval communications affecting investor decisions.
Two student entrepreneurs, Brandon Garcia and Abiha Haider, won the NFTE New York Metro Youth Entrepreneurship Showcase and will advance to the U.S. National Youth Entrepreneurship Showcase in New York City this fall. Brandon's business, ProspectPath...
Teamshares Inc. finalized its business combination with Live Oak Acquisition Corp. V after shareholder approval on June 16, 2026. The deal included a $126.5 million capital raise through a PIPE investment from institutional investors and Teamshares m...
Hengdian World Studios saw a major spike in visitors after the Chinese drama Pursuit of Jade, filmed mostly at the studio, topped international streaming charts and search volumes in 15 countries. During the May holiday, over 80,000 tourists visited ...
The global sputtering equipment market is projected to grow from USD 2.41 billion in 2025 to USD 4.19 billion by 2035, at a CAGR of 5.83%. Growth is fueled by rising demand for high-performance semiconductors, flat panel displays, and photovoltaic so...
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
